Neurology Specific Literature Search   
 
[home][thesaurus]
    

Differential
(Click to cross reference)
abortion, spontaneous
advances in neurology
adverse drug reaction
alemtuzumab
algorithm
anti JC virus antibodies
asymptomatic
biologic markers
brain biopsy
brain biopsy, false negative
brain biopsy, negative
candida albicans
carcinoma
central nervous system, infection of
cerebellar lesion
cerebrospinal fluid
cerebrovascular accident, secondary prevention
children
cladribine
complications
controversies in neurology
cop 1
daclizumab
demyelinating disease
dermatomyositis
disability rating scale, neurological
disability, neurological
disease modifying agents
drug holiday
drug induced neurologic disorders
drug withdrawal
efficacy
encephalitis
encephalitis, viral
eosinophilia
Epstein-Barr virus
Epstein-Barr virus, negative
evidence-based research
false negative
fetus
fingolimod
fingolimod, discontinuation
fumarate
gadolinium
gammaglobulin therapy, intravenous
Guillain Barre syndrome
heralding manifestation
herpes simplex encephalitis
herpes zoster
highly active antiretroviral therapy
hypereosinophilic syndrome(HES)
hypersensitivity reaction
iatrogenic neurologic disorders
immune reconstitution inflammatory syndrome
immunomodulation
immunosuppression
immunosuppressive agents
immunotherapy
in situ hybridization
infection
infliximab
interferon
interferon beta 1-a
interferon beta 1-b
intrauterine
JC virus
life expectancy
lymphoma
lymphoma, primary of CNS
medication withdrawal
melanoma, malignant
misdiagnosis
monoclonal antibodies
MRI
MRI, abnormal
MRI, contrast enhanced
MRI, magnetization transfer sequence
MRI, punctate pattern
MRI, ring sign, open
MRI, serial
MRI, spinal cord
multiple sclerosis
multiple sclerosis, children
multiple sclerosis, diagnosis of
multiple sclerosis, differential diagnosis of
multiple sclerosis, disability status scale
multiple sclerosis, disease activity
multiple sclerosis, misdiagnosis
multiple sclerosis, plaque
multiple sclerosis, relapsing
multiple sclerosis, treatment of
myelitis
natalizumab
natalizumab antibodies
natalizumab, discontinuation
negative
neurologic complications
neurologic disease, diagnoses of
neuromyelitis optica (Devic's disease)
neuropathology
neuropathy
neuropathy, iatrogenic
neuropathy, immune
neuropathy, medication induced
neuropathy, motor, multifocal
neuropathy, peripheral, treatment
neurotoxic
nevus
opportunistic infection
opportunistic infection, CNS
pericarditis
plasmapheresis
plasmapheresis, complications of
polymerase chain reaction
polymerase chain reaction, false negative
polymyositis
polyneuropathy, chronic inflammatory demyelinating
posterior leukoencephalopathy syndrome
postpartum
practice guidelines
preclinical
pregnancy, neurologic complications in
prevention of neurologic disorders
prognosis
progressive multifocal leucoencephalopathy
quality of life
rebound
recurrent
regional enteritis
review article
risk factors
risk stratification
risk-benefit assessment
rituximab
safety
screening
serologic testing
seropositive
skin, lesions in neurologic disorders
spinal cord
steroid therapy, CNS treatment and complications with
teriflunomide
treatment of neurologic disorder
urticaria
vaccination, neurologic complications with
vaccine
varicella zoster virus
viral infection
viral infection, CNS
viral infection, reactivation
viral load
viremia
viruria
visual acuity
visual loss
white matter disease
workup
Showing articles 0 to 50 of 68 Next >>

Adverse Events Associated with Disease-Modifying Drugs for Multiple Sclerosis
Neurol 102:e208006, Ng, HS.,et al, 2024

Infection Risks Among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
JAMA Neurol 77:184-191, Luna, G.,et al, 2020

Maternal and Fetal Risks of Natalizumab Exposure in Utero
Neurol 90:443-444, Marrie, R.A.,et al, 2018

Use of Newer Disease-Modifying Therapies in Pediatric Multiple Sclerosis in the US
Neurol 91:e1778-e1787, Krysko, K.M.,et al, 2018

Natalizumab-Associated PML
Neurol 88:1197-1205, Schwab, N.,et al, 2017

Natalizumab-Related PML 2 Weeks after Negative Anti-JCV Antibody Assay
Neurol 86:484-486, Gagne, M.S.,et al, 2016

Punctate Pattern, A promising imaging marker for the diagnosis of natalizumab-associated PML
Neurol 86:1516-1523, Hodel, J.,et al, 2016

Rebound Syndrome in Patients with Multiple Sclerosis after Cessation of Fingolimod Treatment
JAMA Neurol 73:790-794, Hatcher, S.E.,et al, 2016

Treatment of Relapsing-Remitting Multiple Sclerosis After 24 Doses of Natalizumab
JAMA Neurol 71:954-960, Clerico, M.,et al, 2014

Varicella-Zoster Virus Acute Myelitis in a Patient with MS Treated with Natalizumab
Neurol 80:1812-1813, Yeung, J.,et al, 2013

Natalizumab-Associated PML Identified in the Presymptomatic Phase Using MRI Surveillance
Neurol 78:507-508, Blair,N.F.,et al, 2012

Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
NEJM 366:1870-1880,1938, Bloomgren, G.,et al, 2012

Severe Relapses under Fingolimod Treatment Prescribed after Natalizumab
Neurol 79:2004-2006,1942, Centonze, D.,et al, 2012

Herpes Encephalitis During Natalizumab Tretament in Multiple Sclerosis
Mult Scler J 18:909-911, Kwiatkowski, A.,et al, 2012

Immune Reconstitution Inflammatory Syndrome in Patients With Multiple Sclerosis Following Cessation of Natalizumab Therapy
Arch Neurol 68:186-191, Miravalle,A.,et al, 2011

Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy
Neurol 76:1697-1704, Vermersch,P.,et al, 2011

Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis
Neurol 76:1858-1865, OConnor, P.W.,et al, 2011

Primary Central Nervous System Lymphoma in a Patient Treated with Natalizumab
Ann Neurol 69:1060-1062, Phan-Ba, R.,et al, 2011

Immune Reconstitution Inflammatory Syndrome in Natalizumab-Associated PML
Neurol 77:1061-1067,1033, Tan, I.L.,et al, 2011

Hypereosinophilia in Patients with Multiple Sclerosis Treated with Natalizumab
Neurol 77:1561-1564, Abbas, M.,et al, 2011

Management and Outcome of CSF-JC Virus PCR-negative PML in a Natalizumab-treated Patient with MS
Neurol 77:2010-2016, Kuhle, J.,et al, 2011

Severe Cutaneous Candida Infection During Natalizumab Therapy in Multiple Sclerosis
Neurol 74:521-523, Gutwinski,S.,et al, 2010

Giant Urticaria and Persistent Neutralizing Antibodies After the First Natalizumab Infusion
Neurol 74:1394-1395, Cohen,M., et al, 2010

Natalizumab and Progressive Multifocal Leukoencephalopathy: What are the Causal Factors and Can It be Avoided?
Arch Neurol 67:923-930, Warnke,C., et al, 2010

Natalizumab Treatment in a Patient With Chronic Inflammatory Demyelinating Polyneuropathy
Arch Neurol 67:881-883, Wolf,C., et al, 2010

Safety and Efficacy of Natalizumab in Children With Multiple Sclerosis
Neurol 75:912-917, Ghezzi,A.,et al, 2010

Progressive Multifocal Leukoencephalopathy: Can We Reduce Risk in Patients Receiving Biological Immunomodulatory Therapies?
Ann Neurol 68:271-274, Tyler,K., 2010

Successful Management of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy and Immune Reconstitution Syndrome in a Patient With Multiple Sclerosis
Arch Neurol 67:1391-1394, Schr�der,A.,et al, 2010

Immunologic, Clinical, and Radiologic Status 14 Months After Cessation of Natalizumab Therapy
Neurol 72:396-401,392, Stuve,O.,et al, 2009

Opportunistic Infections and Other Risks with Newer Multiple Sclerosis Therapies
Ann Neurol 65:367-377, Berger,J.R. &Houff,S., 2009

Recurrent Pericarditis Due to Natalizumab Treatment
Neurol 72:1616-1617, Cohen,M.,et al, 2009

Progressive Multifocal Leukoencephalopathy and Relapsing-Remitting Multiple Sclerosis: A Comparative Study
Arch Neurol 66:593-599, Boster,A.,et al, 2009

Primary Central Nervous System Lymphoma in a Patient Treated with Natalizumab
Ann Neurol 66:403-406, 261, 262, Schweikert,A.,et al, 2009

Natalizumab and Central Nervous System Lymphoma: No Clear Association
Ann Neurol 66:261-262, Bozic,C.,et al, 2009

Natalizumab: A Double-Edged Sword?
Ann Neurol 66:262-263, DeAngelis,L., 2009

The Present Efficacy of Multiple Sclerosis Therapeutics
Neurol 73:984-990, Klawiter,E.,et al, 2009

Progressive Multifocal Leukoencephalopathy After Natalizumab Monotherapy
NEJM 361:1081-1087, Linda,H.,et al, 2009

Asymptomatic Reactivation of JC Virus in Patients Treated with Natalizumab
NEJM 361:1067-1074, Chen,Y.,et al, 2009

Treatment of Progressive Multifocal Leukoencephalopathy Associated with Natalizumab
NEJM 361:1075-1080, Wenning,W.,et al, 2009

Reemergence of PML in Natalizumab-Treated Patients--New Cases, Same Concerns
NEJM 361:1041-1043, Major,E., 2009

Best Practice Recommendations for the Selection and Management of Patients with Multiple Sclerosis Receiving Natalizumab Therapy
Mutliple Sclerosis 15:S26-S36, Coyle,P.K.,et al, 2009

Melanoma Complicating Treatment with Natalizumab for Multiple Sclerosis
NEJM 358:647-648, Mullen,J.T.,et al, 2008

Postwithdrawal Rebound Increase in T2 Lesional Activity in Natalizumab-Treated MS Patients
Neurol 70:1150-1151,1073, Vellinga,M.M.,et al, 2008

Assessment: The Use of Natalizumab (Tysabri) for the Treatment of Multiple Sclerosis (An Evidence-Based Review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 71:766-773, Goodin,D.S.,et al., 2008

Monoclonal Antibody Therapies and Neurologic Disorders
Arch Neurol 65:1162-1165, Novack,J.C.,et al., 2008

Natalizumab Use in Pediatric Multiple Sclerosis
Arch Neurol 65:1655-1658, Huppke,P.,et al, 2008

Reactivation of JC Virus and Development of PML in Patients With Multiple Sclerosis
Neurol 68:985-990, Khalili,K.,et al, 2007

Natalizumab Reduces Visual Loss in Patients with Relapsing Multiple Sclerosis
Neurol 68:1299-1302, Balcer,L.J.,et al, 2007

Quantifying the Risks and Benefits of Natalizumab in Relapsing Multiple Sclerosis
Neurol 68:1524-1528, Dorsey,E.R.,et al, 2007



Showing articles 0 to 50 of 68 Next >>